Lymphoma

>

Latest News

Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
FDA Grants Orphan Drug Designation to Tirabrutinib in Primary CNS Lymphoma

March 29th 2023

Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.

Data from a prospective pilot study indicate that circulating tumor DNA may be a valuable prognostic biomarker in early-stage follicular lymphoma.
Basal ctDNA May Predict Treatment Outcomes in Follicular Lymphoma

March 9th 2023

Cutaneous T-Cell Lymphoma: Current and Emerging Therapies
Cutaneous T-Cell Lymphoma: Current and Emerging Therapies

March 1st 2023

A qualitative, interview-based analysis identified 7 distinct roles played by hematologists relating to shared decision making for patients with advanced lymphoma or leukemia.
Multidisciplinary Teams Are Needed for Multidimensional Support in Blood Cancers

February 23rd 2023

The FDA states that the refusal to file letter for SGX301 in early-stage cutaneous T-cell lymphoma was because the new drug application was insufficient for permit substantive review.
FDA Declines to File New Drug Application for SGX301 in T-Cell Lymphoma

February 20th 2023

<1
...
3031323334